Imaging Features and Metastatic Patterns of Advanced ALK-Rearranged Non-Small Cell Lung Cancer

被引:17
|
作者
Mendoza, Dexter P. [1 ]
Lin, Jessica J. [2 ,3 ]
Rooney, Marguerite M. [2 ,3 ]
Chen, Tianqi [4 ]
Sequist, Lecia V. [2 ,3 ]
Shaw, Alice T. [2 ,3 ]
Digumarthy, Subba R. [1 ]
机构
[1] Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St,Founders 202, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA
[4] Harvard Med Sch, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA
关键词
ALK; anaplastic lymphoma kinase; lung cancer; metastasis; FACTOR RECEPTOR MUTATION; EML4-ALK FUSION GENE; CLINICORADIOLOGIC CHARACTERISTICS; OPEN-LABEL; CRIZOTINIB; ADENOCARCINOMA; FISH; EGFR; GEFITINIB; ALECTINIB;
D O I
10.2214/AJR.19.21982
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
OBJECTIVE. ALK rearrangements are an established targetable oncogenic driver in non-small cell lung cancer (NSCLC). The goal of this study was to determine the imaging features of the primary tumor and metastatic patterns in advanced ALK-rearranged (ALK+) NSCLC that may be different from those in EGFR-mutant (EGFR+) or EGFR/ALK wild-type (EGFR-/ALK-) NSCLC. MATERIALS AND METHODS. Patients with advanced ALK+, EGFR+, or EGFR-/ ALK- NSCLC were retrospectively identified. Two radiologists concurrently assessed the imaging features of the primary tumor and the distribution of metastases in these patients. RESULTS. We identified a cohort of 333 patients with metastatic NSCLC (119 ALK+ cases, 116 EGFR+ cases, and 98 EGFR-/ALK- cases). Compared with EGFR+ and EGFR-/ ALK- NSCLC, the primary tumor in ALK+ NSCLC was more likely to be located in the lower lobes (53% of ALK+, 34% of EGFR+, and 36% of EGFR-/ALK- tumors; p < 0.05), less likely to be subsolid (1% of ALK+, 11% of EGFR+, and 8% of EGFR-/ALK- tumors; p < 0.02), and less likely to have air bronchograms (7% of ALK+, 28% of EGFR+, and 29% of EGFR-TALK- tumors; p < 0.01). Compared with EGFR+ and EGFR-TALK- tumors, ALK+ tumors had higher frequencies of distant nodal metastasis (20% of ALK+ tumors vs 2% of EGFR+ and 9% of EGFR-/ALK- tumors; p < 0.05) and lymphangitic carcinomatosis (37% of ALK+ tumors vs 12% of EGFR+ and 12% of EGFR-/ALK- tumors; p < 0.01), but ALK+ tumors had a lower frequency of brain metastasis compared with EGFR+ tumors (24% vs 41%; p = 0.01). Although there was no statistically significant difference in the frequencies of bone metastasis among the three groups, sclerotic bone metastases were more common in the ALK+ tumors (22% vs 7% of EGFR+ tumors and 6% of EGFR-/ALK- tumors; p < 0.01). CONCLUSION. Advanced ALK+ NSCLC has primary tumor imaging features and patterns of metastasis that are different from those of EGFR+ or EGFR-ALK- wild type NSCLC at the time of initial presentation.
引用
收藏
页码:766 / 774
页数:9
相关论文
共 50 条
  • [1] Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer
    Zhu, Viola
    Ou, S. H.
    [J]. EXPERT OPINION ON DRUG SAFETY, 2017, 16 (04) : 509 - 514
  • [2] Clinicopathological Features in Elderly ALK-rearranged Non-small Cell Lung Cancer Patients
    Miyazaki, Kunihiko
    Sato, Shinya
    Kodama, Takahide
    Numata, Takeshi
    Endo, Takeo
    Yamamoto, Yusuke
    Shimizu, Kei
    Yamada, Hideyasu
    Hayashihara, Kenji
    Okauchi, Shinichiro
    Satoh, Hiroaki
    Yamada, Yutaka
    Tamura, Tomohiro
    Saito, Kazuto
    Kikuchi, Norihiro
    Kurishima, Koichi
    Ishikawa, Hiroichi
    Watanabe, Hiroko
    Shiozawa, Toshihiro
    Hizawa, Nobuyuki
    Funayama, Yasunori
    Hayashi, Shigen
    Nakamura, Hiroyuki
    Yamashita, Takaaki
    [J]. IN VIVO, 2020, 34 (04): : 2001 - 2007
  • [3] Alectinib: A Review of Its Use in Advanced ALK-Rearranged Non-Small Cell Lung Cancer
    Kate McKeage
    [J]. Drugs, 2015, 75 : 75 - 82
  • [4] Cardiac Toxicity of Crizotinib Therapy in Advanced ALK-Rearranged Non-Small Cell Lung Cancer
    Zhang, Yan
    Wang, Yan
    Li, Junling
    Hao, Xuezhi
    Ma, Di
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S377 - S377
  • [5] Alectinib: A Review of Its Use in Advanced ALK-Rearranged Non-Small Cell Lung Cancer
    McKeage, Kate
    [J]. DRUGS, 2015, 75 (01) : 75 - 82
  • [6] The Treatment Choice Based on Radiographic Features for Metastatic Brain Tumors in ALK-Rearranged Non-small Cell Lung Cancer
    Chu, L.
    Li, R.
    Yang, X.
    Xia, F.
    Zhang, X.
    Chu, J.
    Zhu, Z.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E510 - E510
  • [7] TARGETING ALK-REARRANGED NON-SMALL CELL LUNG CARCINOMA
    Iafrate, J.
    Kwak, E.
    Bang, Y.
    Solomon, B.
    Shaw, A.
    Camidge, D. R.
    Ou, S. H.
    Maki, R.
    Salgia, R.
    Clark, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (05) : S20 - S20
  • [8] Cystic brain metastases in ALK-rearranged non-small cell lung cancer
    Marta, Guilherme Nader
    da Cunha Colombo Bonadio, Renata Rodrigues
    Martins, Renata Eiras
    Zuppani, Henrique Bortot
    de Castro Junior, Gilberto
    [J]. ECANCERMEDICALSCIENCE, 2018, 12
  • [9] New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer
    Laird Cameron
    Benjamin Solomon
    [J]. Current Treatment Options in Oncology, 2015, 16
  • [10] Overcoming crizotinib resistance in ALK-rearranged non-small cell lung cancer
    Qi, Xiaolong
    Ma, Wang
    Li, Sen
    Zhou, Caicun
    [J]. LUNG CANCER, 2014, 85 (02) : 335 - 336